nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—Azacitidine—Gemcitabine—pancreatic cancer	0.139	0.512	CrCrCtD
Cladribine—Decitabine—Gemcitabine—pancreatic cancer	0.133	0.488	CrCrCtD
Cladribine—POLE—Gemcitabine—pancreatic cancer	0.121	0.235	CbGbCtD
Cladribine—RRM2—Gemcitabine—pancreatic cancer	0.0803	0.156	CbGbCtD
Cladribine—RRM1—Gemcitabine—pancreatic cancer	0.0803	0.156	CbGbCtD
Cladribine—POLA1—Gemcitabine—pancreatic cancer	0.0694	0.135	CbGbCtD
Cladribine—SLC28A3—Gemcitabine—pancreatic cancer	0.0694	0.135	CbGbCtD
Cladribine—DCK—Gemcitabine—pancreatic cancer	0.0427	0.083	CbGbCtD
Cladribine—ABCG2—Tamoxifen—pancreatic cancer	0.0106	0.0205	CbGbCtD
Cladribine—ABCG2—Erlotinib—pancreatic cancer	0.00898	0.0175	CbGbCtD
Cladribine—ABCG2—Irinotecan—pancreatic cancer	0.00811	0.0158	CbGbCtD
Cladribine—ABCG2—Fluorouracil—pancreatic cancer	0.00778	0.0151	CbGbCtD
Cladribine—ABCG2—Docetaxel—pancreatic cancer	0.00594	0.0116	CbGbCtD
Cladribine—ABCG2—Sunitinib—pancreatic cancer	0.00592	0.0115	CbGbCtD
Cladribine—ABCG2—Doxorubicin—pancreatic cancer	0.00443	0.00861	CbGbCtD
Cladribine—POLE3—islet of Langerhans—pancreatic cancer	0.00176	0.102	CbGeAlD
Cladribine—SLC28A3—islet of Langerhans—pancreatic cancer	0.00165	0.0952	CbGeAlD
Cladribine—RRM2B—pancreas—pancreatic cancer	0.00131	0.0756	CbGeAlD
Cladribine—POLE3—pancreas—pancreatic cancer	0.00124	0.0715	CbGeAlD
Cladribine—PNP—digestive system—pancreatic cancer	0.0012	0.0696	CbGeAlD
Cladribine—NR5A1—pancreas—pancreatic cancer	0.0012	0.0693	CbGeAlD
Cladribine—SLC28A3—pancreas—pancreatic cancer	0.00116	0.0669	CbGeAlD
Cladribine—POLE3—digestive system—pancreatic cancer	0.00106	0.0611	CbGeAlD
Cladribine—Floxuridine—TYMP—pancreatic cancer	0.00105	0.276	CrCbGaD
Cladribine—SLC28A3—digestive system—pancreatic cancer	0.000988	0.0571	CbGeAlD
Cladribine—RRM1—islet of Langerhans—pancreatic cancer	0.000918	0.0531	CbGeAlD
Cladribine—Trifluridine—TYMP—pancreatic cancer	0.000831	0.219	CrCbGaD
Cladribine—Fludarabine—SLC29A1—pancreatic cancer	0.000826	0.218	CrCbGaD
Cladribine—POLE—digestive system—pancreatic cancer	0.000805	0.0466	CbGeAlD
Cladribine—DCK—islet of Langerhans—pancreatic cancer	0.000713	0.0412	CbGeAlD
Cladribine—RRM2—digestive system—pancreatic cancer	0.000663	0.0384	CbGeAlD
Cladribine—RRM1—pancreas—pancreatic cancer	0.000645	0.0373	CbGeAlD
Cladribine—RRM1—digestive system—pancreatic cancer	0.000551	0.0319	CbGeAlD
Cladribine—POLE2—Topotecan—Irinotecan—pancreatic cancer	0.000546	0.177	CbGdCrCtD
Cladribine—SLC22A2—digestive system—pancreatic cancer	0.000517	0.0299	CbGeAlD
Cladribine—DCK—pancreas—pancreatic cancer	0.000501	0.029	CbGeAlD
Cladribine—Floxuridine—TYMS—pancreatic cancer	0.000492	0.13	CrCbGaD
Cladribine—DCK—digestive system—pancreatic cancer	0.000428	0.0248	CbGeAlD
Cladribine—Trifluridine—TYMS—pancreatic cancer	0.000391	0.103	CrCbGaD
Cladribine—PNP—Paclitaxel—Docetaxel—pancreatic cancer	0.000296	0.0958	CbGdCrCtD
Cladribine—RRM2—Gefitinib—Erlotinib—pancreatic cancer	0.000292	0.0946	CbGdCrCtD
Cladribine—PNP—Gefitinib—Erlotinib—pancreatic cancer	0.000284	0.0919	CbGdCrCtD
Cladribine—DCK—Topotecan—Irinotecan—pancreatic cancer	0.000246	0.0797	CbGdCrCtD
Cladribine—Adenosine monophosphate—SRC—pancreatic cancer	0.000212	0.0559	CrCbGaD
Cladribine—POLE2—Idarubicin—Epirubicin—pancreatic cancer	0.000128	0.0416	CbGdCrCtD
Cladribine—POLE2—Doxorubicin—Epirubicin—pancreatic cancer	0.000128	0.0416	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Epirubicin—pancreatic cancer	0.000128	0.0416	CbGdCrCtD
Cladribine—RRM1—Azacitidine—Gemcitabine—pancreatic cancer	0.000126	0.0407	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—pancreatic cancer	0.000119	0.0385	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—pancreatic cancer	0.000119	0.0385	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—pancreatic cancer	0.000119	0.0385	CbGdCrCtD
Cladribine—POLE2—Azacitidine—Gemcitabine—pancreatic cancer	9.93e-05	0.0321	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Epirubicin—pancreatic cancer	9.91e-05	0.0321	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Doxorubicin—pancreatic cancer	9.17e-05	0.0297	CbGdCrCtD
Cladribine—RRM2—Azacitidine—Gemcitabine—pancreatic cancer	7.88e-05	0.0255	CbGdCrCtD
Cladribine—DCK—Clomifene—Tamoxifen—pancreatic cancer	7.58e-05	0.0246	CbGdCrCtD
Cladribine—Muscular weakness—Epirubicin—pancreatic cancer	6.36e-05	0.000547	CcSEcCtD
Cladribine—Pain—Gemcitabine—pancreatic cancer	6.33e-05	0.000544	CcSEcCtD
Cladribine—Constipation—Gemcitabine—pancreatic cancer	6.33e-05	0.000544	CcSEcCtD
Cladribine—Nausea—Erlotinib—pancreatic cancer	6.33e-05	0.000544	CcSEcCtD
Cladribine—Decreased appetite—Fluorouracil—pancreatic cancer	6.33e-05	0.000544	CcSEcCtD
Cladribine—Diarrhoea—Sunitinib—pancreatic cancer	6.31e-05	0.000543	CcSEcCtD
Cladribine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	6.28e-05	0.00054	CcSEcCtD
Cladribine—Ataxia—Doxorubicin—pancreatic cancer	6.27e-05	0.000539	CcSEcCtD
Cladribine—Feeling abnormal—Irinotecan—pancreatic cancer	6.26e-05	0.000538	CcSEcCtD
Cladribine—Back pain—Docetaxel—pancreatic cancer	6.23e-05	0.000535	CcSEcCtD
Cladribine—Pain—Fluorouracil—pancreatic cancer	6.22e-05	0.000535	CcSEcCtD
Cladribine—Gastrointestinal pain—Irinotecan—pancreatic cancer	6.21e-05	0.000534	CcSEcCtD
Cladribine—Eosinophilia—Epirubicin—pancreatic cancer	6.17e-05	0.00053	CcSEcCtD
Cladribine—Dizziness—Sunitinib—pancreatic cancer	6.1e-05	0.000524	CcSEcCtD
Cladribine—Feeling abnormal—Gemcitabine—pancreatic cancer	6.1e-05	0.000524	CcSEcCtD
Cladribine—Body temperature increased—Irinotecan—pancreatic cancer	6.01e-05	0.000516	CcSEcCtD
Cladribine—Abdominal pain—Irinotecan—pancreatic cancer	6.01e-05	0.000516	CcSEcCtD
Cladribine—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	6.01e-05	0.000516	CcSEcCtD
Cladribine—Feeling abnormal—Fluorouracil—pancreatic cancer	6e-05	0.000516	CcSEcCtD
Cladribine—Anaemia—Docetaxel—pancreatic cancer	5.95e-05	0.000511	CcSEcCtD
Cladribine—Pancytopenia—Epirubicin—pancreatic cancer	5.92e-05	0.000509	CcSEcCtD
Cladribine—Muscular weakness—Doxorubicin—pancreatic cancer	5.88e-05	0.000506	CcSEcCtD
Cladribine—Vomiting—Sunitinib—pancreatic cancer	5.87e-05	0.000504	CcSEcCtD
Cladribine—Body temperature increased—Gemcitabine—pancreatic cancer	5.85e-05	0.000503	CcSEcCtD
Cladribine—Neutropenia—Epirubicin—pancreatic cancer	5.83e-05	0.000501	CcSEcCtD
Cladribine—Rash—Sunitinib—pancreatic cancer	5.82e-05	0.0005	CcSEcCtD
Cladribine—Dermatitis—Sunitinib—pancreatic cancer	5.81e-05	0.0005	CcSEcCtD
Cladribine—Upper respiratory tract infection—Epirubicin—pancreatic cancer	5.79e-05	0.000498	CcSEcCtD
Cladribine—DCK—Doxorubicin—Epirubicin—pancreatic cancer	5.79e-05	0.0187	CbGdCrCtD
Cladribine—Urticaria—Fluorouracil—pancreatic cancer	5.78e-05	0.000497	CcSEcCtD
Cladribine—Headache—Sunitinib—pancreatic cancer	5.78e-05	0.000497	CcSEcCtD
Cladribine—Body temperature increased—Fluorouracil—pancreatic cancer	5.75e-05	0.000495	CcSEcCtD
Cladribine—Eosinophilia—Doxorubicin—pancreatic cancer	5.71e-05	0.000491	CcSEcCtD
Cladribine—Cough—Docetaxel—pancreatic cancer	5.62e-05	0.000483	CcSEcCtD
Cladribine—Hypersensitivity—Irinotecan—pancreatic cancer	5.6e-05	0.000481	CcSEcCtD
Cladribine—Pneumonia—Epirubicin—pancreatic cancer	5.59e-05	0.00048	CcSEcCtD
Cladribine—Infestation NOS—Epirubicin—pancreatic cancer	5.56e-05	0.000478	CcSEcCtD
Cladribine—Infestation—Epirubicin—pancreatic cancer	5.56e-05	0.000478	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	5.51e-05	0.000474	CcSEcCtD
Cladribine—Chest pain—Docetaxel—pancreatic cancer	5.48e-05	0.000471	CcSEcCtD
Cladribine—Arthralgia—Docetaxel—pancreatic cancer	5.48e-05	0.000471	CcSEcCtD
Cladribine—Myalgia—Docetaxel—pancreatic cancer	5.48e-05	0.000471	CcSEcCtD
Cladribine—Nausea—Sunitinib—pancreatic cancer	5.48e-05	0.000471	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—pancreatic cancer	5.48e-05	0.000471	CcSEcCtD
Cladribine—Renal failure—Epirubicin—pancreatic cancer	5.46e-05	0.000469	CcSEcCtD
Cladribine—Asthenia—Irinotecan—pancreatic cancer	5.45e-05	0.000469	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	5.44e-05	0.000468	CcSEcCtD
Cladribine—Conjunctivitis—Epirubicin—pancreatic cancer	5.4e-05	0.000464	CcSEcCtD
Cladribine—Urinary tract infection—Epirubicin—pancreatic cancer	5.4e-05	0.000464	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—pancreatic cancer	5.39e-05	0.000463	CcSEcCtD
Cladribine—Hypersensitivity—Fluorouracil—pancreatic cancer	5.36e-05	0.000461	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	5.36e-05	0.000461	CcSEcCtD
Cladribine—DCK—Epirubicin—Doxorubicin—pancreatic cancer	5.35e-05	0.0173	CbGdCrCtD
Cladribine—Asthenia—Gemcitabine—pancreatic cancer	5.31e-05	0.000457	CcSEcCtD
Cladribine—Confusional state—Docetaxel—pancreatic cancer	5.3e-05	0.000455	CcSEcCtD
Cladribine—Hepatobiliary disease—Epirubicin—pancreatic cancer	5.25e-05	0.000452	CcSEcCtD
Cladribine—Oedema—Docetaxel—pancreatic cancer	5.25e-05	0.000452	CcSEcCtD
Cladribine—Epistaxis—Epirubicin—pancreatic cancer	5.24e-05	0.00045	CcSEcCtD
Cladribine—Pruritus—Gemcitabine—pancreatic cancer	5.24e-05	0.00045	CcSEcCtD
Cladribine—Infection—Docetaxel—pancreatic cancer	5.22e-05	0.000449	CcSEcCtD
Cladribine—Diarrhoea—Irinotecan—pancreatic cancer	5.2e-05	0.000447	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—pancreatic cancer	5.17e-05	0.000444	CcSEcCtD
Cladribine—Nervous system disorder—Docetaxel—pancreatic cancer	5.15e-05	0.000443	CcSEcCtD
Cladribine—Pruritus—Fluorouracil—pancreatic cancer	5.15e-05	0.000443	CcSEcCtD
Cladribine—Thrombocytopenia—Docetaxel—pancreatic cancer	5.14e-05	0.000442	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—pancreatic cancer	5.14e-05	0.000442	CcSEcCtD
Cladribine—Infestation—Doxorubicin—pancreatic cancer	5.14e-05	0.000442	CcSEcCtD
Cladribine—Tachycardia—Docetaxel—pancreatic cancer	5.13e-05	0.000441	CcSEcCtD
Cladribine—Skin disorder—Docetaxel—pancreatic cancer	5.1e-05	0.000439	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	5.1e-05	0.000438	CcSEcCtD
Cladribine—Diarrhoea—Gemcitabine—pancreatic cancer	5.07e-05	0.000435	CcSEcCtD
Cladribine—Renal failure—Doxorubicin—pancreatic cancer	5.05e-05	0.000434	CcSEcCtD
Cladribine—Dizziness—Irinotecan—pancreatic cancer	5.03e-05	0.000432	CcSEcCtD
Cladribine—Haemoglobin—Epirubicin—pancreatic cancer	5.01e-05	0.000431	CcSEcCtD
Cladribine—Anorexia—Docetaxel—pancreatic cancer	5.01e-05	0.00043	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—pancreatic cancer	5e-05	0.00043	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—pancreatic cancer	5e-05	0.00043	CcSEcCtD
Cladribine—Haemorrhage—Epirubicin—pancreatic cancer	4.99e-05	0.000429	CcSEcCtD
Cladribine—Diarrhoea—Fluorouracil—pancreatic cancer	4.98e-05	0.000428	CcSEcCtD
Cladribine—Pharyngitis—Epirubicin—pancreatic cancer	4.95e-05	0.000426	CcSEcCtD
Cladribine—Urinary tract disorder—Epirubicin—pancreatic cancer	4.93e-05	0.000423	CcSEcCtD
Cladribine—Oedema peripheral—Epirubicin—pancreatic cancer	4.91e-05	0.000422	CcSEcCtD
Cladribine—Hypotension—Docetaxel—pancreatic cancer	4.91e-05	0.000422	CcSEcCtD
Cladribine—Connective tissue disorder—Epirubicin—pancreatic cancer	4.9e-05	0.000421	CcSEcCtD
Cladribine—Urethral disorder—Epirubicin—pancreatic cancer	4.89e-05	0.00042	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	4.86e-05	0.000418	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—pancreatic cancer	4.85e-05	0.000417	CcSEcCtD
Cladribine—Vomiting—Irinotecan—pancreatic cancer	4.83e-05	0.000415	CcSEcCtD
Cladribine—Dizziness—Fluorouracil—pancreatic cancer	4.81e-05	0.000414	CcSEcCtD
Cladribine—Rash—Irinotecan—pancreatic cancer	4.79e-05	0.000412	CcSEcCtD
Cladribine—Dermatitis—Irinotecan—pancreatic cancer	4.79e-05	0.000412	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	4.79e-05	0.000411	CcSEcCtD
Cladribine—Headache—Irinotecan—pancreatic cancer	4.76e-05	0.000409	CcSEcCtD
Cladribine—Insomnia—Docetaxel—pancreatic cancer	4.75e-05	0.000408	CcSEcCtD
Cladribine—Paraesthesia—Docetaxel—pancreatic cancer	4.72e-05	0.000406	CcSEcCtD
Cladribine—Erythema multiforme—Epirubicin—pancreatic cancer	4.72e-05	0.000405	CcSEcCtD
Cladribine—Vomiting—Gemcitabine—pancreatic cancer	4.71e-05	0.000405	CcSEcCtD
Cladribine—Dyspnoea—Docetaxel—pancreatic cancer	4.68e-05	0.000403	CcSEcCtD
Cladribine—Somnolence—Docetaxel—pancreatic cancer	4.67e-05	0.000401	CcSEcCtD
Cladribine—Rash—Gemcitabine—pancreatic cancer	4.67e-05	0.000401	CcSEcCtD
Cladribine—Dermatitis—Gemcitabine—pancreatic cancer	4.66e-05	0.000401	CcSEcCtD
Cladribine—Eye disorder—Epirubicin—pancreatic cancer	4.66e-05	0.000401	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—pancreatic cancer	4.64e-05	0.000399	CcSEcCtD
Cladribine—Headache—Gemcitabine—pancreatic cancer	4.64e-05	0.000399	CcSEcCtD
Cladribine—Cardiac disorder—Epirubicin—pancreatic cancer	4.63e-05	0.000398	CcSEcCtD
Cladribine—Vomiting—Fluorouracil—pancreatic cancer	4.63e-05	0.000398	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—pancreatic cancer	4.62e-05	0.000397	CcSEcCtD
Cladribine—Rash—Fluorouracil—pancreatic cancer	4.59e-05	0.000395	CcSEcCtD
Cladribine—Dermatitis—Fluorouracil—pancreatic cancer	4.59e-05	0.000394	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—pancreatic cancer	4.58e-05	0.000394	CcSEcCtD
Cladribine—Decreased appetite—Docetaxel—pancreatic cancer	4.57e-05	0.000393	CcSEcCtD
Cladribine—Headache—Fluorouracil—pancreatic cancer	4.56e-05	0.000392	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—pancreatic cancer	4.56e-05	0.000392	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—pancreatic cancer	4.55e-05	0.000391	CcSEcCtD
Cladribine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.54e-05	0.00039	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—pancreatic cancer	4.54e-05	0.00039	CcSEcCtD
Cladribine—Fatigue—Docetaxel—pancreatic cancer	4.53e-05	0.000389	CcSEcCtD
Cladribine—Angiopathy—Epirubicin—pancreatic cancer	4.53e-05	0.000389	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—pancreatic cancer	4.52e-05	0.000389	CcSEcCtD
Cladribine—Nausea—Irinotecan—pancreatic cancer	4.51e-05	0.000388	CcSEcCtD
Cladribine—Immune system disorder—Epirubicin—pancreatic cancer	4.51e-05	0.000387	CcSEcCtD
Cladribine—Mediastinal disorder—Epirubicin—pancreatic cancer	4.5e-05	0.000386	CcSEcCtD
Cladribine—Pain—Docetaxel—pancreatic cancer	4.49e-05	0.000386	CcSEcCtD
Cladribine—Constipation—Docetaxel—pancreatic cancer	4.49e-05	0.000386	CcSEcCtD
Cladribine—Chills—Epirubicin—pancreatic cancer	4.48e-05	0.000385	CcSEcCtD
Cladribine—Arrhythmia—Epirubicin—pancreatic cancer	4.46e-05	0.000383	CcSEcCtD
Cladribine—Alopecia—Epirubicin—pancreatic cancer	4.41e-05	0.000379	CcSEcCtD
Cladribine—Nausea—Gemcitabine—pancreatic cancer	4.4e-05	0.000378	CcSEcCtD
Cladribine—Mental disorder—Epirubicin—pancreatic cancer	4.37e-05	0.000376	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—pancreatic cancer	4.36e-05	0.000375	CcSEcCtD
Cladribine—Malnutrition—Epirubicin—pancreatic cancer	4.34e-05	0.000373	CcSEcCtD
Cladribine—Erythema—Epirubicin—pancreatic cancer	4.34e-05	0.000373	CcSEcCtD
Cladribine—Feeling abnormal—Docetaxel—pancreatic cancer	4.33e-05	0.000372	CcSEcCtD
Cladribine—Nausea—Fluorouracil—pancreatic cancer	4.32e-05	0.000372	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—pancreatic cancer	4.31e-05	0.000371	CcSEcCtD
Cladribine—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.3e-05	0.000369	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—pancreatic cancer	4.28e-05	0.000368	CcSEcCtD
Cladribine—Flatulence—Epirubicin—pancreatic cancer	4.28e-05	0.000368	CcSEcCtD
Cladribine—Back pain—Epirubicin—pancreatic cancer	4.2e-05	0.000361	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—pancreatic cancer	4.19e-05	0.00036	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—pancreatic cancer	4.17e-05	0.000358	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—pancreatic cancer	4.16e-05	0.000358	CcSEcCtD
Cladribine—Abdominal pain—Docetaxel—pancreatic cancer	4.15e-05	0.000357	CcSEcCtD
Cladribine—Body temperature increased—Docetaxel—pancreatic cancer	4.15e-05	0.000357	CcSEcCtD
Cladribine—Chills—Doxorubicin—pancreatic cancer	4.14e-05	0.000356	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	4.14e-05	0.000566	CbGpPWpGaD
Cladribine—Arrhythmia—Doxorubicin—pancreatic cancer	4.12e-05	0.000354	CcSEcCtD
Cladribine—POLE—Mitotic G1-G1/S phases—MYC—pancreatic cancer	4.08e-05	0.000558	CbGpPWpGaD
Cladribine—Alopecia—Doxorubicin—pancreatic cancer	4.08e-05	0.000351	CcSEcCtD
Cladribine—NR5A1—Gene Expression—NOTCH3—pancreatic cancer	4.06e-05	0.000554	CbGpPWpGaD
Cladribine—DCK—Metabolism—PRSS1—pancreatic cancer	4.05e-05	0.000554	CbGpPWpGaD
Cladribine—PNP—Metabolism—CD44—pancreatic cancer	4.05e-05	0.000553	CbGpPWpGaD
Cladribine—Mental disorder—Doxorubicin—pancreatic cancer	4.04e-05	0.000348	CcSEcCtD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—pancreatic cancer	4.03e-05	0.000551	CbGpPWpGaD
Cladribine—Ill-defined disorder—Epirubicin—pancreatic cancer	4.03e-05	0.000346	CcSEcCtD
Cladribine—Erythema—Doxorubicin—pancreatic cancer	4.02e-05	0.000345	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—pancreatic cancer	4.02e-05	0.000345	CcSEcCtD
Cladribine—Anaemia—Epirubicin—pancreatic cancer	4.01e-05	0.000345	CcSEcCtD
Cladribine—RRM1—Metabolism—TYMP—pancreatic cancer	3.99e-05	0.000545	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	3.96e-05	0.000542	CbGpPWpGaD
Cladribine—Flatulence—Doxorubicin—pancreatic cancer	3.96e-05	0.00034	CcSEcCtD
Cladribine—Malaise—Epirubicin—pancreatic cancer	3.92e-05	0.000337	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	3.91e-05	0.000535	CbGpPWpGaD
Cladribine—POLA1—S Phase—CCND1—pancreatic cancer	3.91e-05	0.000534	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	3.91e-05	0.000534	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—RB1—pancreatic cancer	3.9e-05	0.000534	CbGpPWpGaD
Cladribine—Back pain—Doxorubicin—pancreatic cancer	3.89e-05	0.000334	CcSEcCtD
Cladribine—PNP—Metabolism—GCG—pancreatic cancer	3.88e-05	0.000531	CbGpPWpGaD
Cladribine—Hypersensitivity—Docetaxel—pancreatic cancer	3.87e-05	0.000333	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—TYMS—pancreatic cancer	3.86e-05	0.000528	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	3.84e-05	0.000526	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—HSPA1A—pancreatic cancer	3.84e-05	0.000525	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	3.83e-05	0.000524	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP2—pancreatic cancer	3.81e-05	0.000521	CbGpPWpGaD
Cladribine—Cough—Epirubicin—pancreatic cancer	3.79e-05	0.000326	CcSEcCtD
Cladribine—Asthenia—Docetaxel—pancreatic cancer	3.77e-05	0.000324	CcSEcCtD
Cladribine—RRM2—Metabolism—ARG2—pancreatic cancer	3.76e-05	0.000514	CbGpPWpGaD
Cladribine—Ill-defined disorder—Doxorubicin—pancreatic cancer	3.73e-05	0.00032	CcSEcCtD
Cladribine—Pruritus—Docetaxel—pancreatic cancer	3.72e-05	0.00032	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—pancreatic cancer	3.71e-05	0.000319	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—TYMS—pancreatic cancer	3.71e-05	0.000507	CbGpPWpGaD
Cladribine—Myalgia—Epirubicin—pancreatic cancer	3.7e-05	0.000318	CcSEcCtD
Cladribine—Chest pain—Epirubicin—pancreatic cancer	3.7e-05	0.000318	CcSEcCtD
Cladribine—Arthralgia—Epirubicin—pancreatic cancer	3.7e-05	0.000318	CcSEcCtD
Cladribine—Anxiety—Epirubicin—pancreatic cancer	3.68e-05	0.000317	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.67e-05	0.000316	CcSEcCtD
Cladribine—Discomfort—Epirubicin—pancreatic cancer	3.65e-05	0.000314	CcSEcCtD
Cladribine—PNP—Metabolism—STK11—pancreatic cancer	3.65e-05	0.000499	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	3.65e-05	0.000499	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—BRCA2—pancreatic cancer	3.63e-05	0.000497	CbGpPWpGaD
Cladribine—POLA1—Mitotic G1-G1/S phases—CCND1—pancreatic cancer	3.63e-05	0.000496	CbGpPWpGaD
Cladribine—Malaise—Doxorubicin—pancreatic cancer	3.62e-05	0.000311	CcSEcCtD
Cladribine—RRM2B—Metabolism—TYMS—pancreatic cancer	3.62e-05	0.000495	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	3.62e-05	0.000495	CbGpPWpGaD
Cladribine—Diarrhoea—Docetaxel—pancreatic cancer	3.59e-05	0.000309	CcSEcCtD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	3.58e-05	0.00049	CbGpPWpGaD
Cladribine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—pancreatic cancer	3.58e-05	0.000489	CbGpPWpGaD
Cladribine—Confusional state—Epirubicin—pancreatic cancer	3.57e-05	0.000307	CcSEcCtD
Cladribine—Oedema—Epirubicin—pancreatic cancer	3.54e-05	0.000305	CcSEcCtD
Cladribine—Infection—Epirubicin—pancreatic cancer	3.52e-05	0.000303	CcSEcCtD
Cladribine—DCK—Metabolism—ARG2—pancreatic cancer	3.51e-05	0.00048	CbGpPWpGaD
Cladribine—Cough—Doxorubicin—pancreatic cancer	3.51e-05	0.000301	CcSEcCtD
Cladribine—POLE2—Cell Cycle—RB1—pancreatic cancer	3.49e-05	0.000477	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—BRCA2—pancreatic cancer	3.49e-05	0.000477	CbGpPWpGaD
Cladribine—Nervous system disorder—Epirubicin—pancreatic cancer	3.48e-05	0.000299	CcSEcCtD
Cladribine—Dizziness—Docetaxel—pancreatic cancer	3.47e-05	0.000299	CcSEcCtD
Cladribine—Thrombocytopenia—Epirubicin—pancreatic cancer	3.47e-05	0.000298	CcSEcCtD
Cladribine—Tachycardia—Epirubicin—pancreatic cancer	3.46e-05	0.000297	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TYMS—pancreatic cancer	3.46e-05	0.000472	CbGpPWpGaD
Cladribine—POLA1—G1/S Transition—MYC—pancreatic cancer	3.45e-05	0.000472	CbGpPWpGaD
Cladribine—Skin disorder—Epirubicin—pancreatic cancer	3.44e-05	0.000296	CcSEcCtD
Cladribine—POLE2—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	3.43e-05	0.000469	CbGpPWpGaD
Cladribine—Hyperhidrosis—Epirubicin—pancreatic cancer	3.43e-05	0.000294	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—pancreatic cancer	3.42e-05	0.000294	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—pancreatic cancer	3.42e-05	0.000294	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—pancreatic cancer	3.42e-05	0.000294	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—pancreatic cancer	3.41e-05	0.000293	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.4e-05	0.000292	CcSEcCtD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	3.4e-05	0.000464	CbGpPWpGaD
Cladribine—Discomfort—Doxorubicin—pancreatic cancer	3.38e-05	0.00029	CcSEcCtD
Cladribine—Anorexia—Epirubicin—pancreatic cancer	3.38e-05	0.00029	CcSEcCtD
Cladribine—POLE—Mitotic M-M/G1 phases—RB1—pancreatic cancer	3.36e-05	0.00046	CbGpPWpGaD
Cladribine—Vomiting—Docetaxel—pancreatic cancer	3.34e-05	0.000287	CcSEcCtD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	3.32e-05	0.000454	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TYMS—pancreatic cancer	3.32e-05	0.000453	CbGpPWpGaD
Cladribine—Rash—Docetaxel—pancreatic cancer	3.31e-05	0.000285	CcSEcCtD
Cladribine—Hypotension—Epirubicin—pancreatic cancer	3.31e-05	0.000285	CcSEcCtD
Cladribine—Dermatitis—Docetaxel—pancreatic cancer	3.31e-05	0.000284	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—pancreatic cancer	3.31e-05	0.000284	CcSEcCtD
Cladribine—Headache—Docetaxel—pancreatic cancer	3.29e-05	0.000283	CcSEcCtD
Cladribine—RRM2—Metabolism—TYMP—pancreatic cancer	3.29e-05	0.000449	CbGpPWpGaD
Cladribine—Oedema—Doxorubicin—pancreatic cancer	3.28e-05	0.000282	CcSEcCtD
Cladribine—Infection—Doxorubicin—pancreatic cancer	3.26e-05	0.00028	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.23e-05	0.000278	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—pancreatic cancer	3.22e-05	0.000276	CcSEcCtD
Cladribine—RRM1—Metabolism—GLP1R—pancreatic cancer	3.22e-05	0.00044	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	3.21e-05	0.00044	CbGpPWpGaD
Cladribine—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.21e-05	0.000276	CcSEcCtD
Cladribine—Insomnia—Epirubicin—pancreatic cancer	3.21e-05	0.000276	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—pancreatic cancer	3.2e-05	0.000275	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—pancreatic cancer	3.18e-05	0.000274	CcSEcCtD
Cladribine—Paraesthesia—Epirubicin—pancreatic cancer	3.18e-05	0.000274	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.17e-05	0.000272	CcSEcCtD
Cladribine—RRM1—Metabolism—DPYD—pancreatic cancer	3.16e-05	0.000433	CbGpPWpGaD
Cladribine—Dyspnoea—Epirubicin—pancreatic cancer	3.16e-05	0.000272	CcSEcCtD
Cladribine—Somnolence—Epirubicin—pancreatic cancer	3.15e-05	0.000271	CcSEcCtD
Cladribine—PNP—Metabolism—TYMS—pancreatic cancer	3.14e-05	0.000429	CbGpPWpGaD
Cladribine—POLA1—S Phase—MYC—pancreatic cancer	3.14e-05	0.000429	CbGpPWpGaD
Cladribine—Anorexia—Doxorubicin—pancreatic cancer	3.13e-05	0.000269	CcSEcCtD
Cladribine—Nausea—Docetaxel—pancreatic cancer	3.12e-05	0.000268	CcSEcCtD
Cladribine—Decreased appetite—Epirubicin—pancreatic cancer	3.08e-05	0.000265	CcSEcCtD
Cladribine—DCK—Metabolism—TYMP—pancreatic cancer	3.07e-05	0.00042	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—CDKN2A—pancreatic cancer	3.07e-05	0.000419	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	3.07e-05	0.000419	CbGpPWpGaD
Cladribine—Hypotension—Doxorubicin—pancreatic cancer	3.06e-05	0.000263	CcSEcCtD
Cladribine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.06e-05	0.000263	CcSEcCtD
Cladribine—Fatigue—Epirubicin—pancreatic cancer	3.06e-05	0.000263	CcSEcCtD
Cladribine—NR5A1—Gene Expression—SMAD4—pancreatic cancer	3.05e-05	0.000418	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	3.04e-05	0.000416	CbGpPWpGaD
Cladribine—Pain—Epirubicin—pancreatic cancer	3.03e-05	0.00026	CcSEcCtD
Cladribine—Constipation—Epirubicin—pancreatic cancer	3.03e-05	0.00026	CcSEcCtD
Cladribine—RRM2—Cell Cycle—TERT—pancreatic cancer	3.01e-05	0.000412	CbGpPWpGaD
Cladribine—RRM1—Metabolism—SLC2A2—pancreatic cancer	3e-05	0.00041	CbGpPWpGaD
Cladribine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	2.99e-05	0.000257	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—pancreatic cancer	2.97e-05	0.000255	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—pancreatic cancer	2.94e-05	0.000253	CcSEcCtD
Cladribine—RRM2B—Metabolism—APOE—pancreatic cancer	2.94e-05	0.000402	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—CTNNB1—pancreatic cancer	2.92e-05	0.0004	CbGpPWpGaD
Cladribine—Dyspnoea—Doxorubicin—pancreatic cancer	2.92e-05	0.000251	CcSEcCtD
Cladribine—Feeling abnormal—Epirubicin—pancreatic cancer	2.92e-05	0.000251	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—pancreatic cancer	2.91e-05	0.000251	CcSEcCtD
Cladribine—POLA1—Mitotic G1-G1/S phases—MYC—pancreatic cancer	2.91e-05	0.000398	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—CCND1—pancreatic cancer	2.9e-05	0.000396	CbGpPWpGaD
Cladribine—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.9e-05	0.000249	CcSEcCtD
Cladribine—POLE—Cell Cycle—TERT—pancreatic cancer	2.89e-05	0.000395	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP9—pancreatic cancer	2.87e-05	0.000392	CbGpPWpGaD
Cladribine—Decreased appetite—Doxorubicin—pancreatic cancer	2.85e-05	0.000245	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.83e-05	0.000243	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—pancreatic cancer	2.83e-05	0.000243	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	2.82e-05	0.000386	CbGpPWpGaD
Cladribine—Urticaria—Epirubicin—pancreatic cancer	2.82e-05	0.000242	CcSEcCtD
Cladribine—Constipation—Doxorubicin—pancreatic cancer	2.8e-05	0.000241	CcSEcCtD
Cladribine—Pain—Doxorubicin—pancreatic cancer	2.8e-05	0.000241	CcSEcCtD
Cladribine—Abdominal pain—Epirubicin—pancreatic cancer	2.8e-05	0.000241	CcSEcCtD
Cladribine—Body temperature increased—Epirubicin—pancreatic cancer	2.8e-05	0.000241	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	2.75e-05	0.000376	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	2.72e-05	0.000372	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.71e-05	0.000371	CbGpPWpGaD
Cladribine—Feeling abnormal—Doxorubicin—pancreatic cancer	2.7e-05	0.000232	CcSEcCtD
Cladribine—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.68e-05	0.00023	CcSEcCtD
Cladribine—RRM2B—Metabolism—PIK3CG—pancreatic cancer	2.66e-05	0.000363	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	2.65e-05	0.000363	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GLP1R—pancreatic cancer	2.65e-05	0.000362	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—SRC—pancreatic cancer	2.64e-05	0.000361	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—TYMS—pancreatic cancer	2.64e-05	0.000361	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—RB1—pancreatic cancer	2.62e-05	0.000358	CbGpPWpGaD
Cladribine—Hypersensitivity—Epirubicin—pancreatic cancer	2.61e-05	0.000224	CcSEcCtD
Cladribine—RRM2—Metabolism—DPYD—pancreatic cancer	2.61e-05	0.000356	CbGpPWpGaD
Cladribine—Urticaria—Doxorubicin—pancreatic cancer	2.6e-05	0.000224	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—pancreatic cancer	2.59e-05	0.000223	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—pancreatic cancer	2.59e-05	0.000223	CcSEcCtD
Cladribine—POLE2—Cell Cycle—CCND1—pancreatic cancer	2.59e-05	0.000354	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—VEGFA—pancreatic cancer	2.57e-05	0.000352	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PPARG—pancreatic cancer	2.56e-05	0.000351	CbGpPWpGaD
Cladribine—PNP—Metabolism—APOE—pancreatic cancer	2.55e-05	0.000349	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—STAT3—pancreatic cancer	2.55e-05	0.000348	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—NRAS—pancreatic cancer	2.54e-05	0.000348	CbGpPWpGaD
Cladribine—Asthenia—Epirubicin—pancreatic cancer	2.54e-05	0.000219	CcSEcCtD
Cladribine—NR5A1—Generic Transcription Pathway—MYC—pancreatic cancer	2.52e-05	0.000344	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—RB1—pancreatic cancer	2.51e-05	0.000344	CbGpPWpGaD
Cladribine—Pruritus—Epirubicin—pancreatic cancer	2.51e-05	0.000216	CcSEcCtD
Cladribine—POLA1—Cell Cycle—BRCA2—pancreatic cancer	2.48e-05	0.00034	CbGpPWpGaD
Cladribine—DCK—Metabolism—GLP1R—pancreatic cancer	2.47e-05	0.000338	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SLC2A2—pancreatic cancer	2.47e-05	0.000338	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	2.46e-05	0.000336	CbGpPWpGaD
Cladribine—DCK—Metabolism—DPYD—pancreatic cancer	2.43e-05	0.000333	CbGpPWpGaD
Cladribine—Diarrhoea—Epirubicin—pancreatic cancer	2.42e-05	0.000208	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—pancreatic cancer	2.42e-05	0.000208	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	2.4e-05	0.000328	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—RB1—pancreatic cancer	2.4e-05	0.000328	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TYMS—pancreatic cancer	2.36e-05	0.000323	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TGFB1—pancreatic cancer	2.36e-05	0.000323	CbGpPWpGaD
Cladribine—Asthenia—Doxorubicin—pancreatic cancer	2.35e-05	0.000202	CcSEcCtD
Cladribine—Dizziness—Epirubicin—pancreatic cancer	2.34e-05	0.000201	CcSEcCtD
Cladribine—RRM2—Cell Cycle—RB1—pancreatic cancer	2.34e-05	0.00032	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CD—pancreatic cancer	2.34e-05	0.000319	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CD44—pancreatic cancer	2.32e-05	0.000318	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—MYC—pancreatic cancer	2.32e-05	0.000318	CbGpPWpGaD
Cladribine—Pruritus—Doxorubicin—pancreatic cancer	2.32e-05	0.000199	CcSEcCtD
Cladribine—NR5A1—Developmental Biology—EGFR—pancreatic cancer	2.32e-05	0.000317	CbGpPWpGaD
Cladribine—DCK—Metabolism—SLC2A2—pancreatic cancer	2.31e-05	0.000316	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CG—pancreatic cancer	2.3e-05	0.000315	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	2.3e-05	0.000315	CbGpPWpGaD
Cladribine—Vomiting—Epirubicin—pancreatic cancer	2.25e-05	0.000194	CcSEcCtD
Cladribine—NR5A1—Gene Expression—NOTCH1—pancreatic cancer	2.25e-05	0.000308	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—RB1—pancreatic cancer	2.25e-05	0.000307	CbGpPWpGaD
Cladribine—Diarrhoea—Doxorubicin—pancreatic cancer	2.24e-05	0.000193	CcSEcCtD
Cladribine—Rash—Epirubicin—pancreatic cancer	2.23e-05	0.000192	CcSEcCtD
Cladribine—Dermatitis—Epirubicin—pancreatic cancer	2.23e-05	0.000192	CcSEcCtD
Cladribine—RRM1—Metabolism—GCG—pancreatic cancer	2.23e-05	0.000305	CbGpPWpGaD
Cladribine—PNP—Metabolism—PPARG—pancreatic cancer	2.22e-05	0.000304	CbGpPWpGaD
Cladribine—Headache—Epirubicin—pancreatic cancer	2.22e-05	0.000191	CcSEcCtD
Cladribine—POLE—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	2.21e-05	0.000302	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—TNF—pancreatic cancer	2.21e-05	0.000302	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	2.2e-05	0.000301	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	2.2e-05	0.000301	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—KRAS—pancreatic cancer	2.19e-05	0.000299	CbGpPWpGaD
Cladribine—Dizziness—Doxorubicin—pancreatic cancer	2.17e-05	0.000186	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	2.16e-05	0.000295	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—PPARG—pancreatic cancer	2.12e-05	0.000291	CbGpPWpGaD
Cladribine—Nausea—Epirubicin—pancreatic cancer	2.1e-05	0.000181	CcSEcCtD
Cladribine—RRM1—Metabolism—STK11—pancreatic cancer	2.1e-05	0.000287	CbGpPWpGaD
Cladribine—Vomiting—Doxorubicin—pancreatic cancer	2.08e-05	0.000179	CcSEcCtD
Cladribine—POLE2—Cell Cycle—MYC—pancreatic cancer	2.08e-05	0.000284	CbGpPWpGaD
Cladribine—Rash—Doxorubicin—pancreatic cancer	2.07e-05	0.000178	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—pancreatic cancer	2.07e-05	0.000178	CcSEcCtD
Cladribine—RRM2—Cell Cycle—CDKN2A—pancreatic cancer	2.06e-05	0.000282	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TERT—pancreatic cancer	2.06e-05	0.000281	CbGpPWpGaD
Cladribine—Headache—Doxorubicin—pancreatic cancer	2.05e-05	0.000177	CcSEcCtD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	2.05e-05	0.000281	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	2.04e-05	0.000279	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CB—pancreatic cancer	2.04e-05	0.000278	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CD—pancreatic cancer	2.03e-05	0.000277	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—pancreatic cancer	2.02e-05	0.000276	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CDKN2A—pancreatic cancer	1.98e-05	0.00027	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	1.97e-05	0.00027	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	1.96e-05	0.000267	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	1.95e-05	0.000267	CbGpPWpGaD
Cladribine—Nausea—Doxorubicin—pancreatic cancer	1.95e-05	0.000167	CcSEcCtD
Cladribine—RRM2—Cell Cycle, Mitotic—CCND1—pancreatic cancer	1.95e-05	0.000266	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CD44—pancreatic cancer	1.91e-05	0.000262	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.87e-05	0.000256	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—CCND1—pancreatic cancer	1.87e-05	0.000255	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—HRAS—pancreatic cancer	1.86e-05	0.000254	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GCG—pancreatic cancer	1.84e-05	0.000251	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	1.82e-05	0.000249	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.81e-05	0.000248	CbGpPWpGaD
Cladribine—RRM1—Metabolism—TYMS—pancreatic cancer	1.8e-05	0.000246	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—RB1—pancreatic cancer	1.79e-05	0.000245	CbGpPWpGaD
Cladribine—DCK—Metabolism—CD44—pancreatic cancer	1.79e-05	0.000245	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CB—pancreatic cancer	1.77e-05	0.000241	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTEN—pancreatic cancer	1.76e-05	0.000241	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—pancreatic cancer	1.75e-05	0.000239	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—CCND1—pancreatic cancer	1.74e-05	0.000238	CbGpPWpGaD
Cladribine—RRM2—Metabolism—STK11—pancreatic cancer	1.73e-05	0.000236	CbGpPWpGaD
Cladribine—DCK—Metabolism—GCG—pancreatic cancer	1.72e-05	0.000234	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—pancreatic cancer	1.71e-05	0.000233	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—CCND1—pancreatic cancer	1.67e-05	0.000228	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—AKT1—pancreatic cancer	1.64e-05	0.000225	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PRSS1—pancreatic cancer	1.62e-05	0.000222	CbGpPWpGaD
Cladribine—DCK—Metabolism—STK11—pancreatic cancer	1.61e-05	0.00022	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PRSS1—pancreatic cancer	1.6e-05	0.000219	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—RB1—pancreatic cancer	1.6e-05	0.000219	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	1.58e-05	0.000215	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—MYC—pancreatic cancer	1.56e-05	0.000213	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.53e-05	0.000209	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTEN—pancreatic cancer	1.53e-05	0.000209	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—pancreatic cancer	1.5e-05	0.000205	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PRSS1—pancreatic cancer	1.5e-05	0.000204	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TYMS—pancreatic cancer	1.48e-05	0.000203	CbGpPWpGaD
Cladribine—RRM1—Metabolism—APOE—pancreatic cancer	1.47e-05	0.0002	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—pancreatic cancer	1.41e-05	0.000193	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ARG2—pancreatic cancer	1.41e-05	0.000192	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—pancreatic cancer	1.4e-05	0.000191	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ARG2—pancreatic cancer	1.39e-05	0.00019	CbGpPWpGaD
Cladribine—DCK—Metabolism—TYMS—pancreatic cancer	1.39e-05	0.00019	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—pancreatic cancer	1.34e-05	0.000183	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—pancreatic cancer	1.33e-05	0.000182	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CG—pancreatic cancer	1.32e-05	0.000181	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ARG2—pancreatic cancer	1.3e-05	0.000177	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PPARG—pancreatic cancer	1.28e-05	0.000175	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—pancreatic cancer	1.24e-05	0.00017	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMP—pancreatic cancer	1.23e-05	0.000168	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMP—pancreatic cancer	1.22e-05	0.000166	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—pancreatic cancer	1.21e-05	0.000166	CbGpPWpGaD
Cladribine—RRM2—Metabolism—APOE—pancreatic cancer	1.21e-05	0.000165	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—pancreatic cancer	1.19e-05	0.000163	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CD—pancreatic cancer	1.16e-05	0.000159	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—pancreatic cancer	1.15e-05	0.000157	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMP—pancreatic cancer	1.13e-05	0.000155	CbGpPWpGaD
Cladribine—DCK—Metabolism—APOE—pancreatic cancer	1.13e-05	0.000154	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—pancreatic cancer	1.1e-05	0.00015	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CG—pancreatic cancer	1.09e-05	0.000149	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—pancreatic cancer	1.08e-05	0.000147	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—pancreatic cancer	1.07e-05	0.000146	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PPARG—pancreatic cancer	1.05e-05	0.000144	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CG—pancreatic cancer	1.02e-05	0.000139	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—pancreatic cancer	1.01e-05	0.000139	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CB—pancreatic cancer	1.01e-05	0.000139	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—pancreatic cancer	1e-05	0.000137	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GLP1R—pancreatic cancer	9.9e-06	0.000135	CbGpPWpGaD
Cladribine—DCK—Metabolism—PPARG—pancreatic cancer	9.83e-06	0.000134	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GLP1R—pancreatic cancer	9.8e-06	0.000134	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—DPYD—pancreatic cancer	9.74e-06	0.000133	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—DPYD—pancreatic cancer	9.64e-06	0.000132	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CD—pancreatic cancer	9.58e-06	0.000131	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—pancreatic cancer	9.54e-06	0.00013	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SLC2A2—pancreatic cancer	9.24e-06	0.000126	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SLC2A2—pancreatic cancer	9.15e-06	0.000125	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GLP1R—pancreatic cancer	9.13e-06	0.000125	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—pancreatic cancer	9.03e-06	0.000123	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—DPYD—pancreatic cancer	8.99e-06	0.000123	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CD—pancreatic cancer	8.95e-06	0.000122	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—pancreatic cancer	8.79e-06	0.00012	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—pancreatic cancer	8.76e-06	0.00012	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SLC2A2—pancreatic cancer	8.53e-06	0.000117	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—pancreatic cancer	8.42e-06	0.000115	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—pancreatic cancer	8.4e-06	0.000115	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CB—pancreatic cancer	8.35e-06	0.000114	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—pancreatic cancer	8.27e-06	0.000113	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—pancreatic cancer	7.84e-06	0.000107	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CB—pancreatic cancer	7.8e-06	0.000107	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—pancreatic cancer	7.73e-06	0.000106	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—pancreatic cancer	7.21e-06	9.86e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CD44—pancreatic cancer	7.16e-06	9.79e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CD44—pancreatic cancer	7.09e-06	9.69e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—pancreatic cancer	6.92e-06	9.46e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GCG—pancreatic cancer	6.86e-06	9.38e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GCG—pancreatic cancer	6.79e-06	9.29e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—pancreatic cancer	6.74e-06	9.22e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CD44—pancreatic cancer	6.6e-06	9.03e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—STK11—pancreatic cancer	6.45e-06	8.82e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—pancreatic cancer	6.45e-06	8.82e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—STK11—pancreatic cancer	6.39e-06	8.73e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GCG—pancreatic cancer	6.33e-06	8.66e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—pancreatic cancer	6.18e-06	8.45e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—STK11—pancreatic cancer	5.95e-06	8.14e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMS—pancreatic cancer	5.55e-06	7.59e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMS—pancreatic cancer	5.49e-06	7.51e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMS—pancreatic cancer	5.12e-06	7e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—pancreatic cancer	5.09e-06	6.96e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—pancreatic cancer	5.05e-06	6.9e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—pancreatic cancer	4.76e-06	6.5e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—APOE—pancreatic cancer	4.51e-06	6.17e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—APOE—pancreatic cancer	4.47e-06	6.11e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—APOE—pancreatic cancer	4.16e-06	5.69e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—pancreatic cancer	4.16e-06	5.68e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CG—pancreatic cancer	4.07e-06	5.57e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CG—pancreatic cancer	4.03e-06	5.51e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPARG—pancreatic cancer	3.93e-06	5.38e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPARG—pancreatic cancer	3.89e-06	5.32e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—pancreatic cancer	3.89e-06	5.31e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CG—pancreatic cancer	3.76e-06	5.14e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPARG—pancreatic cancer	3.63e-06	4.96e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CD—pancreatic cancer	3.58e-06	4.9e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CD—pancreatic cancer	3.54e-06	4.85e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CD—pancreatic cancer	3.3e-06	4.52e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CB—pancreatic cancer	3.12e-06	4.27e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—pancreatic cancer	3.09e-06	4.23e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CB—pancreatic cancer	3.09e-06	4.22e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—pancreatic cancer	3.06e-06	4.19e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CB—pancreatic cancer	2.88e-06	3.94e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—pancreatic cancer	2.85e-06	3.9e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—pancreatic cancer	2.7e-06	3.69e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—pancreatic cancer	2.67e-06	3.65e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—pancreatic cancer	2.49e-06	3.4e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—pancreatic cancer	1.9e-06	2.6e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	1.88e-06	2.58e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	1.76e-06	2.4e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—pancreatic cancer	1.55e-06	2.13e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—pancreatic cancer	1.54e-06	2.1e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—pancreatic cancer	1.43e-06	1.96e-05	CbGpPWpGaD
